<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01337011</url>
  </required_header>
  <id_info>
    <org_study_id>1884</org_study_id>
    <secondary_id>2009-013103-63</secondary_id>
    <nct_id>NCT01337011</nct_id>
  </id_info>
  <brief_title>Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells</brief_title>
  <acronym>AlsterMACS</acronym>
  <official_title>Pilot Study Comparing the Effect of Intra-coronary Versus Intramyocardial Application of Enriched CD133pos Autologous Bone Marrow Derived Stem Cells for Improving Left Ventricular Function in Chronic Ischemic Cardiomyopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asklepios proresearch</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Miltenyi Biomedicine GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asklepios proresearch</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot study comparing the effect of intra-coronary versus intramyocardial&#xD;
      application of enriched CD133pos autologous bone marrow derived stem cells for improving left&#xD;
      ventricular function in chronic ischemic cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent years have seen a tremendous improvement of possibilities to restore normal cardiac&#xD;
      perfusion of the coronary arteries both by surgical and interventional techniques. In&#xD;
      addition, several pharmacological approaches are available to block the mal-adaptive&#xD;
      molecular signaling initiated by the Renin/Angiotensin/Aldosteron (RAAS) system. Device&#xD;
      therapy achieving resychronisation has lowered morbidity and mortality. However, heart&#xD;
      failure therapy still falls short to address the underlying disease of the heart muscle: loss&#xD;
      of contractile force.&#xD;
&#xD;
      To achieve this aim and restore contractile force a regenerative approach is required. Early&#xD;
      experimental studies suggested bone marrow cells to be able to differentiate towards&#xD;
      functional cardiomyocytes when injected into the scar area after ischemic injury.2 These and&#xD;
      other studies lead to clinical trials, where bone marrow cells were injected into the&#xD;
      coronary circulation. Lately, the first completed multi-center, placebo-controlled,&#xD;
      double-blinded study found several end points to be improved including global left&#xD;
      ventricular function 3. At the same time genetically labelled experimental mouse models&#xD;
      demonstrated differentiation of bone marrow cells towards a cardiomyocyte lineage to be a&#xD;
      rare event,4 questioning at least the proposed molecular and cellular mechanism of&#xD;
      intra-coronary cell therapy. Furthermore, several other clinical trials recently performed&#xD;
      did either find no or a very limited effect of intra-coronary applied bone marrow cells. The&#xD;
      effect appears to be related to improved angiogenesis. Our group has recently shown that in&#xD;
      mammals endogenous regeneration of myocardium does occur after injury and can be enhanced via&#xD;
      specific signaling pathways.5 Whether intra-coronary cell therapy is the ideal approach to&#xD;
      enhance this process is currently unclear.&#xD;
&#xD;
      References:&#xD;
&#xD;
        1. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, Hochadel M,&#xD;
           Komajda M, Lassus J, Lopez-Sendon JL, Ponikowski P, Tavazzi L. EuroHeart Failure Survey&#xD;
           II (EHFS II): a survey on hospitalized acute heart failure patients: description of&#xD;
           population. Eur Heart J. 2006;27:2725-2736.&#xD;
&#xD;
        2. Orlic D, Kajstura J, Chimenti S, Limana F, Jakoniuk I, Quaini F, Nadal-Ginard B, Bodine&#xD;
           DM, Leri A, Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving&#xD;
           function and survival. Proc Natl Acad Sci U S A. 2001;98:10344-10349.&#xD;
&#xD;
        3. Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, Yu J,&#xD;
           Corti R, Mathey DG, Hamm CW, Suselbeck T, Assmus B, Tonn T, Dimmeler S, Zeiher AM, the&#xD;
           R-AMII. Intracoronary Bone Marrow-Derived Progenitor Cells in Acute Myocardial&#xD;
           Infarction. N Engl J Med. 2006;355:1210-1221.&#xD;
&#xD;
        4. Murry CE, Soonpaa MH, Reinecke H, Nakajima H, Nakajima HO, Rubart M, Pasumarthi KB,&#xD;
           Virag JI, Bartelmez SH, Poppa V, Bradford G, Dowell JD, Williams DA, Field LJ.&#xD;
           Haematopoietic stem cells do not transdifferentiate into cardiac myocytes in myocardial&#xD;
           infarcts. Nature. 2004;428:664-668.&#xD;
&#xD;
        5. Zelarayan L, Noack C, Sekkali B, Kmecova J, Gehrke C, Renger A, Zafiriou MP, Nagel Rvd,&#xD;
           Dietz R, Windt LJd, Balligand J-L, Bergmann MW. beta-catenin downregulation attenuates&#xD;
           ischemic cardiac remodeling through enhanced resident precursor cell differentiation.&#xD;
           Proc Natl Acad Sci U S A. 2008;105:19762-19767.&#xD;
&#xD;
        6. Krause KT, Jaquet K, Geidel S, Schneider C, Mandel C, Stoll HP, Hertting K, Harle T,&#xD;
           Kuck KH. Percutaneous endocardial injection of erythropoietin: assessment of&#xD;
           cardioprotection by electromechanical mapping. Eur J Heart Fail. 2006;8:443-450.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    study was stopped due to funding issues&#xD;
  </why_stopped>
  <start_date type="Actual">July 2011</start_date>
  <completion_date type="Actual">July 17, 2017</completion_date>
  <primary_completion_date type="Actual">March 2, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparison of the effect of CD133pos. bone marrow derived stem cells using the intra-myocardial vs. the intra-coronary route of administration for improving left ventricular function in patients with chronic ischemic cardiomopathy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LVEF</measure>
    <time_frame>after 6 to 12 months</time_frame>
    <description>Improvement of global left ventricular function as well as global strain rate as assessed by echocardiography. Transthoracic echocardiography will be performed at baseline and after 6 and 12 month. Images are acquired in the standard parasternal and apical views.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>intra-coronary administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of stem cells using the intra-coronary route.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intra-myocardial administration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of stem cells using the intra-myocardial route.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>autologous CD133pos stem cell application</intervention_name>
    <description>The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.</description>
    <arm_group_label>intra-coronary administration</arm_group_label>
    <arm_group_label>intra-myocardial administration</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 to 80 years old&#xD;
&#xD;
          -  Of female and male gender&#xD;
&#xD;
          -  Patient has reduced ejection fraction as evaluated by routine clinical angiogram,&#xD;
             echocardiography or MRI (≤45%) due to ischemic heart disease&#xD;
&#xD;
          -  symptomatic heart failure NYHA ≥ II on optimal therapy&#xD;
&#xD;
          -  coronary artery in the target region that can be used for cell infusion&#xD;
&#xD;
          -  Patient has been informed of the nature of the clinical trial and agrees to its&#xD;
             provision and has provided written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  planned or performed CABG surgery or PCI within 4 weeks of study entry&#xD;
&#xD;
          -  recent myocardial infarction (&lt; 6 months)&#xD;
&#xD;
          -  TIMI flow &lt; II in the coronary artery selected for infusion&#xD;
&#xD;
          -  cardiogenic shock requiring mechanical ventilation or intra-aortic balloon pump&#xD;
&#xD;
          -  progressive tumor disease&#xD;
&#xD;
          -  primary disease of bone marrow including mal-function of components of the coagulation&#xD;
             system&#xD;
&#xD;
          -  women of child-bearing age premenopausal&#xD;
&#xD;
          -  LV wall thickness &lt; 5mm at planned site of injection&#xD;
&#xD;
          -  ventricular wall thrombus&#xD;
&#xD;
          -  severe aortic valvular heart disease&#xD;
&#xD;
          -  severe atrial or ventricular tachycardia unresponsive to intravenous or oral drug&#xD;
             therapy&#xD;
&#xD;
          -  aneurysm of the anterior wall&#xD;
&#xD;
          -  history of stroke&#xD;
&#xD;
          -  know diseases of the liver resulting in reduced plasmatic coagulation with spontaneous&#xD;
             INR &gt;2&#xD;
&#xD;
          -  patients with chronic infectious diseases (HBV, HCV, HIV, seropositivity for Treponema&#xD;
             pallidum)&#xD;
&#xD;
          -  patients taking part or have taken part in other clinical trials within the past 3&#xD;
             months&#xD;
&#xD;
          -  patients unable to provide informed consent&#xD;
&#xD;
          -  any other medical condition that the enrolling physician deems significant in&#xD;
             representing a potential hazard for the patient when participating in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Bergmann, PD Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asklepios Kliniken Hamburg GmbH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASKLEPIOS Klinik St. Georg</name>
      <address>
        <city>Hamburg</city>
        <zip>20099</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 14, 2011</study_first_submitted>
  <study_first_submitted_qc>April 15, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2011</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Ischemic Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

